| Literature DB >> 35682232 |
Chaofan Li1,2, Nengliang Yao1,2,3, Stephanie L Miller4, Christopher Macpherson4, Taryn Hassinger5, Kaitlin Love6, Steven K Malin4,7,8,9,10.
Abstract
Background: Although Reduced Nicotine Cigarettes (RNC) are suggested to improve smoking cessation and cardiometabolic health in relation to cancer risk, the effectiveness of exercise training with RNC on smoking cessation and cardiometabolic health is unknown.Entities:
Keywords: cardiovascular disease; insulin resistance; obesity; physical activity; smoking cessation
Mesh:
Substances:
Year: 2022 PMID: 35682232 PMCID: PMC9180864 DOI: 10.3390/ijerph19116647
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Effect of RNC with or without Exercise on cardiometabolic health.
| Outcome Variables | Control | RNC | RNC + Exercise | Time X Treatment | Time X Treatment |
|---|---|---|---|---|---|
|
| |||||
| Age | 45.0 ± 12.0 | 38.6 ± 13.0 | 45.7 ± 7.9 | 0.80 | 0.03 |
|
| |||||
| Weight (kg) | 0.07 | 0.29 | |||
| Baseline | 74.7 ± 17.3 | 88.3 ± 12.8 | 81.2 ± 14.8 | ||
| 12 Weeks | 79.0 ± 16.0 | 88.5 ± 12.5 | 80.8 ± 15.4 | ||
| BMI (kg/m2) | 0.51 | 0.09 | |||
| Baseline | 29.2 ± 6.4 | 32.6 ± 4.3 | 31.4 ± 6.9 | ||
| 12 Weeks | 29.7 ± 6.7 | 32.4 ± 4.1 | 31.2 ± 7.0 | ||
| Fat% | 0.90 | 0.01 | |||
| Baseline | 38.1 ± 9.6 | 40.0 ± 5.2 | 43.7 ± 5.0 | ||
| 12 Weeks | 38.2 ± 10.6 | 39.5 ± 6.2 | 43.4 ± 4.3 | ||
| VO2max (mL/kg/min) | 0.20 | 0.18 | |||
| Baseline | 26.8 ± 8.9 | 20.4 ± 4.7 | 22.5 ± 2.8 | ||
| 12 Weeks | 24.0 ± 8.4 | 21.2 ± 4.4 | 23.8 ± 4.7 | ||
| RMR (kcal/day) | 0.54 | 0.08 | |||
| Baseline | 1344.8 ± 202.0 | 1483.3 ± 184.5 | 1302.0 ± 163.4 | ||
| 12 Weeks | 1362.3 ± 219.7 | 1479.7 ± 164.3 | 1301.2 ± 171.0 | ||
| RER | 0.44 | 0.10 | |||
| Baseline | 0.83 ± 0.04 | 0.84 ± 0.05 | 0.82 ± 0.03 | ||
| 12 Weeks | 0.84 ± 0.05 | 0.89 ± 0.08 | 0.82 ± 0.05 | ||
|
| |||||
| Insulin (uIU/mL) ** | 0.13 | 0.25 | |||
| Baseline | 14.6 ± 8.0 | 9.8 ± 7.6 | 6.8 ± 2.2 | ||
| 12 Weeks | 19.2 ± 11.7 a | 15.6 ± 7.9 a | 6.3 ± 2.6 | ||
| Glucose (mg/dL) | 0.50 | 0.10 | |||
| Baseline | 94.5 ± 11.7 | 93.7 ± 7.2 | 95.1 ± 9.3 | ||
| 12 Weeks | 102.8 ± 15.3 | 102.3 ± 17.4 | 94.3 ± 5.5 | ||
| HbA1C (%) | 0.63 | 0.06 | |||
| Baseline | 5.4 ± 0.5 | 5.2 ± 0.3 | 5.5 ± 0.3 | ||
| 12 Weeks | 5.5 ± 0.6 | 5.2 ± 0.4 | 5.5 ± 0.3 | ||
| HOMA-IR * | 0.32 | 0.19 | |||
| Baseline | 2.8 ± 1.2 | 2.2 ± 1.6 | 1.6 ± 0.7 | ||
| 12 Weeks | 4.3 ± 3.2 | 4.1 ± 2.7 | 1.6 ± 0.7 | ||
| Cortisol (μg/dL) | 0.06 | 0.30 | |||
| Baseline | 10.7 ± 3.5 | 8.7 ± 3.2 | 11.3 ± 5.2 | ||
| 12 Weeks | 16.5 ± 3.7 b | 11.1 ± 2.9 | 11.0 ± 3.2 | ||
| hs-CRP (mg/L) | 0.35 | 0.13 | |||
| Baseline | 3.0 ± 2.6 | 2.0 ± 1.7 | 6.3 ± 7.9 | ||
| 12 Weeks | 7.4 ± 9.2 | 1.6 ± 1.2 | 8.3 ± 11.2 | ||
| Leptin (ng/mL) | 0.94 | 0.01 | |||
| Baseline | 18.5 ± 12.9 | 16.2 ± 9.6 | 16.5 ± 10.3 | ||
| 12 Weeks | 20.4 ± 13.9 | 18.0 ± 8.7 | 19.5 ± 9.5 | ||
| TC (mg/dL) ** | 0.12 | 0.23 | |||
| Baseline | 170.7 ± 24.2 | 176.4 ± 35.6 | 206.7 ± 30.7 | ||
| 12 Weeks | 175.3 ± 29.1 | 158.1 ± 27.4 | 208.7 ± 31.1 | ||
| TG (mg/dL) | 0.09 | 0.26 | |||
| Baseline | 102.2 ± 80.0 | 123.4 ± 61.1 | 106.8 ± 79.1 | ||
| 12 Weeks | 134.8 ± 90.8 | 114.4 ± 51.0 | 110.3 ± 67.6 | ||
| HDL (mg/dL) ** | 0.44 | 0.10 | |||
| Baseline | 53.3 ± 7.9 | 43.1 ± 7.5 | 54.2 ± 13.7 | ||
| 12 Weeks | 55.3 ± 10.9 | 41.6 ± 6.3 | 56.8 ± 11.6 | ||
| LDL (mg/dL) * | 0.35 | 0.12 | |||
| Baseline | 110.2 ± 14.0 | 112.9 ± 35.5 | 134.7 ± 23.7 | ||
| 12 Weeks | 97.5 ± 21.9 | 97.6 ± 28.2 | 133.7 ± 26.4 | ||
| TC/HDL | 0.59 | 0.06 | |||
| Baseline | 3.3 ± 0.7 | 4.3 ± 1.4 | 4.0 ± 1.1 | ||
| 12 Weeks | 3.3 ± 0.9 | 3.9 ± 1.0 | 3.8 ± 0.9 | ||
Note: Data are mean (SD), N = 20. There were no significant differences at baseline. * Main effect of treatment was significant at p < 0.10 level; ** Main effect of treatment was significant at p < 0.05 level. a Trending difference between baseline and 12-week post at p < 0.10 level; b Significant difference between baseline and 12-week post at p < 0.05 level; VO2max, insulin, hs-CRP and TG were log-transformed for analysis.
Effect of RNC with and without Exercise on smoking withdrawal scale.
| Outcome Variables | Control | RNC | RNC + Exercise | Time X Treatment | Time X Treatment |
|---|---|---|---|---|---|
|
| |||||
| Wisconsin smoking withdrawal score | 0.82 | 0.02 | |||
| Baseline | 1.9 ± 0.4 | 1.9 ± 0.6 | 1.9 ± 0.2 | ||
| 12 Weeks | 1.9 ± 0.5 | 2.1 ± 0.4 | 1.8 ± 0.5 | ||
| Anger | 0.43 | 0.10 | |||
| Baseline | 2.5 ± 0.6 | 1.9 ± 0.9 | 1.7 ± 1.0 | ||
| 12 Weeks | 1.9 ± 0.8 | 2.2 ± 1.1 | 1.7 ± 0.8 | ||
| Anxiety | 0.39 | 0.11 | |||
| Baseline | 2.4 ± 0.8 | 2.3 ± 1.0 | 2.5 ± 0.7 | ||
| 12 Weeks | 2.1 ± 0.8 | 2.5 ± 0.5 | 2.0 ± 0.8 | ||
| Concentration | 0.79 | 0.03 | |||
| Baseline | 1.6 ± 1.3 | 2.0 ± 0.8 | 1.6 ± 0.4 | ||
| 12 Weeks | 1.5 ± 0.9 | 1.9 ± 0.6 | 1.3 ± 0.5 | ||
| Craving | 0.07 | 0.27 | |||
| Baseline | 2.1 ± 0.7 | 1.9 ± 0.6 | 2.5 ± 0.6 | ||
| 12 Weeks | 2.0 ± 0.9 | 2.4 ± 0.4 | 1.8 ± 0.9 | ||
| Hunger | 0.67 | 0.05 | |||
| Baseline | 2.2 ± 0.8 | 2.3 ± 1.0 | 1.6 ± 0.5 | ||
| 12 Weeks | 2.2 ± 1.0 | 2.6 ± 0.6 | 2.0 ± 0.9 | ||
| Sadness | 0.98 | 0.003 | |||
| Baseline | 1.2 ± 0.4 | 1.5 ± 0.7 | 1.6 ± 0.6 | ||
| 12 Weeks | 1.4 ± 0.6 | 1.6 ± 0.9 | 1.9 ± 0.5 | ||
| Sleep | 0.71 | 0.04 | |||
| Baseline | 1.9 ± 0.7 | 1.7 ± 0.9 | 1.7 ± 0.8 | ||
| 12 Weeks | 1.8 ± 0.9 | 1.5 ± 0.4 | 1.9 ± 1.0 | ||
|
| |||||
| Nicotine Dependence score | 0.08 | 0.25 | |||
| Baseline | 4.9 ± 1.9 | 5.4 ± 2.1 | 5.7 ± 2.5 | ||
| 12 Weeks | 5.1 ± 2.5 | 5.3 ± 1.7 | 3.3 ± 2.7 | ||
| Nicotine (ng/mL) | 0.68 | 0.06 | |||
| Baseline | 636.2 ± 491.0 | 200.3 ± 179.8 | 462.6 ± 440.8 | ||
| 12 Weeks | 582.0 ± 500.5 | 305.8 ± 454.2 | 265.4 ± 523.2 | ||
| Nornicotine (ng/mL) | 0.38 | 0.13 | |||
| Baseline | 62.9 ± 43.9 | 33.4 ± 16.5 | 51.4 ± 30.6 | ||
| 12 Weeks | 68.3 ± 48.3 | 42.7 ± 27.8 | 35.8 ± 47.9 | ||
| Cotinine (ng/mL) | 0.01 | 0.43 | |||
| Baseline | 824.5 ± 379.2 | 899.1 ± 333.6 | 1058.2 ± 314.4 | ||
| 12 Weeks | 921.8 ± 484.3 | 877.9 ± 456.1 | 363.9 ± 471.1 a | ||
| Anabasine (ng/mL) | 0.37 | 0.17 | |||
| Baseline | 11.8 ± 9.9 | 3.5 ± 1.5 | 8.4 ± 2.3 | ||
| 12 Weeks | 11.5 ± 6.9 | 6.4 ± 4.8 | 5.2 ± 7.7 | ||
| CO (ppm) | 0.95 | 0.01 | |||
| Baseline | 1.8 ± 1.1 | 2.1 ± 1.5 | 2.0 ± 2.0 | ||
| 12 Weeks | 1.3 ± 1.7 | 1.3 ± 1.8 | 1.3 ± 0.7 | ||
Note: Data are mean (SD), N = 20. There were no significant differences at baseline. a Trending difference between baseline and 12-week post test at p < 0.10 level.
Figure 1(A). Pearson correlation between nicotine dependence score change and cotinine change. Note: r = 0.52 (p = 0.02). (B). Spearman ranked correlation between nicotine dependence score change and VO2max change. Note: r = −0.50 (p = 0.03).